Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMS
NCT05974852 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 732
Last updated 2026-03-09
Summary
The goal of this non-interventional, observational study is to learn if cortical plexus enhancement in patients with primary progressive multiple sclerosis occurs in response to the autoimmune inflammatory process.
Conditions
Interventions
- OTHER
-
Ocrelizumab
Non-interventional
Sponsors & Collaborators
-
Genentech, Inc.
collaborator INDUSTRY -
State University of New York at Buffalo
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-10-01
- Primary Completion
- 2023-12-30
- Completion
- 2023-12-30
Countries
- United States
Study Locations
More Related Trials
-
A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis
NCT03523858 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Effect of Ocrelizumab on Neuroinflammation in Multiple Sclerosis as Measured by 11C-PBR28 MR-PET Imaging of Microglia Activation
NCT04230174 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis
NCT05906992 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
NCT07067463 ·Status: RECRUITING ·Phase: PHASE3
-
Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714
NCT03691077 ·Status: UNKNOWN ·Phase: PHASE3
-
Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab
NCT04377555 ·Status: COMPLETED ·Phase: PHASE4
-
Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
NCT02807285 ·Status: NO_LONGER_AVAILABLE
-
A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
NCT00676715 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)
NCT02688985 ·Status: COMPLETED ·Phase: PHASE3
-
Ocrelizumab for Preventing Clinical Multiple Sclerosis in Individuals With Radiologically Isolated Disease.
NCT04877457 ·Status: TERMINATED ·Phase: PHASE4
-
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
NCT02861014 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab
NCT03157830 ·Status: COMPLETED
-
Symptom Burden in Patients Treated With Ocrelizumab for Multiple Sclerosis
NCT04855617 ·Status: COMPLETED
-
IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis
NCT06677710 ·Status: SUSPENDED ·Phase: PHASE1
-
A Study to Evaluate the Safety of Administering Ocrelizumab Per a Shorter Infusion Protocol in Participants With Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Multiple Sclerosis (RMS)
NCT03606460 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
NCT07299019 ·Status: RECRUITING ·Phase: PHASE3
-
A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis
NCT04711148 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
NCT02637856 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
NCT04544436 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study to Provide Complementary Efficacy, Safety and Patient Reported Outcomes Data in Participants With Active Relapsing Forms of Multiple Sclerosis (MS) in a Pragmatic Setting
NCT03589105 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis
NCT04261790 ·Status: COMPLETED ·Phase: PHASE4
-
People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists
NCT07207148 ·Status: RECRUITING
-
Mechanism of Action of Ocrelizumab in Multiple Sclerosis
NCT03344094 ·Status: COMPLETED
-
A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis
NCT05232825 ·Status: COMPLETED ·Phase: PHASE3
-
A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis
NCT03972306 ·Status: COMPLETED ·Phase: PHASE1